Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propofol + fentanyl + atracurium besylate is a combination anesthetic regimen used for the induction and maintenance of general anesthesia. Propofol is a short-acting intravenous sedative-hypnotic that acts as a positive allosteric modulator of the GABA-A receptor. Fentanyl is a potent synthetic opioid analgesic that primarily targets the mu-opioid receptor. Atracurium besylate is a non-depolarizing neuromuscular blocking agent that acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction. This combination provides the three pillars of general anesthesia: hypnosis, analgesia, and muscle relaxation. In clinical trial contexts, such as those conducted by Mansoura University, this regimen is used as a standard anesthetic control for procedures like abdominoplasty to evaluate the efficacy of regional nerve blocks for postoperative pain management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propofol + fentanyl + atracurium besylate.